Building a Synthetic Biology Platform
CB Therapeutics aims to become a leader in research, development and production of yeast-based tryptamine, cannabinoids and their analogs.
Download the investor presentation, receive an IPO alert, and subscribe to corporate updates.
Low cost, high purity, environmentally-friendly production in just days.
Management team with a passion for science and a knack for business.
New molecules, IP development, and licensing opportunities.
Robust & Growing Pipeline
Numerous letters of intent worth millions of dollars for various cannabinoids in its pipeline.
Memorandum of Understanding with the Cleveland Clinic to support clinical trials.
Copyright © 2020. All rights reserved.